Blood Irradiation Market Share, Size and Growth Analysis By 2029

The blood irradiation market is anticipated to grow significantly, reaching an estimated US$ 104.37 million by 2028, up from US$ 65.15 million in 2021. This growth represents a compound annual growth rate (CAGR) of 7.0% from 2022 to 2028.

Several factors are contributing to this upward trend, including the rising incidence of both communicable and noncommunicable diseases, increased healthcare spending, and various government initiatives aimed at improving health outcomes. The global population is increasingly affected by a range of health issues, such as cancer, cardiovascular diseases, chronic kidney disease, and strokes. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of mortality worldwide, accounting for approximately 17.9 million deaths annually. Furthermore, the prevalence of communicable diseases, including Hepatitis, influenza, and HIV/AIDS, is also on the rise, further propelling the demand for blood irradiation solutions. In 2020, WHO reported that around 325 million individuals were living with hepatitis B, leading to 900,000 deaths each year due to this infection.

The aging population is another critical factor influencing the market. The number of individuals aged 60 and above was around 1 billion in 2019, projected to rise to 1.4 billion by 2030 and 2.1 billion by 2050. This demographic is particularly vulnerable to noncommunicable diseases, which can be exacerbated by factors such as poor diet, lack of exercise, tobacco use, and alcohol consumption.

Moreover, the demand for blood transfusions is increasing due to a rise in surgical procedures, accidents, trauma cases, and various disorders. The elderly population is particularly susceptible to bloodstream infections, which are a significant cause of morbidity and mortality. The National Library of Medicine estimates that approximately 28,000 bloodstream infections occur globally each year. Increased awareness of these infections and the immune responses associated with transfused blood are also contributing to the market's growth, as irradiated blood is known to enhance immune function and overall patient health, particularly in cancer treatments.

As a result, the combination of rising rates of communicable and noncommunicable diseases, increased blood transfusions, and heightened awareness of bloodstream infections is driving the blood irradiation market forward.

Furthermore, the growing population of immunocompromised individuals, along with the rising incidence of leukemia and lymphoma, presents significant opportunities for market expansion. The American Medical Association reported that in 2021, approximately 2.7% of the adult population in the US, or around 7 million people, were immunocompromised due to conditions such as organ transplants, cancer, and autoimmune disorders. The National Institute of Environmental Health Sciences noted that autoimmune disorders affected over 24 million people in the US in 2021, with prevalence rates ranging from 5% to 8%. Additionally, the increasing rates of cancer diagnoses, with 18.1 million cases reported in 2020, further underscore the need for effective blood irradiation solutions.

Significant growth has also been observed in the incidence of leukemia and lymphoma. The Leukemia and Lymphoma Society estimated that around 186,400 individuals in the US were diagnosed with these conditions in 2021, representing 9.8% of the total new cancer cases that year. This increase in immunocompromised individuals and the prevalence of autoimmune disorders are expected to create substantial opportunities for the blood irradiation market in the near future.

Blood irradiators are essential in the healthcare sector, prompting ongoing research and development efforts that lead to innovative products. For example, in November 2018, JW Bioscience, a subsidiary of JW Pharmaceutical, introduced Sangray, a medical device designed to prevent transfusion-related graft-versus-host disease by using X-rays to irradiate blood bags. Notably, Sangray is Korea's first blood irradiation device that does not utilize Cesium-137, a hazardous radioactive material.

Advancements in alternative technologies, such as proton and ion beam therapies, are also noteworthy. These methods employ high-energy positive ions to treat tumors with greater precision while minimizing damage to surrounding healthy tissues. Other innovative treatments, including FLASH radiotherapy, carbon ion therapy, volumetric-modulated arc therapy, and intensity-modulated radiotherapy, are also gaining traction. These technological advancements are expected to create further opportunities for the blood irradiation market.

Additionally, the growth of partnerships and collaborations between blood centers and large corporations is propelling the blood irradiators market.

Geographical Insights

In 2021, North America dominated the blood irradiation market, with the US holding the largest share. The region's advanced healthcare infrastructure, accessibility to medical facilities, and a strong focus on improving treatment outcomes are expected to drive market growth in the coming years.

Conversely, the Asia Pacific region is projected to experience the highest growth rate during the forecast period. Countries like China, Japan, and India are expected to see significant market expansion, driven by increased investments from international companies, enhanced government support, and improvements in healthcare infrastructure.

Market Segmentation

The blood irradiation market is categorized by type into intravenous laser blood irradiation, transcutaneous laser blood irradiation, and extracorporeal blood irradiation. In 2021, the intravenous laser blood irradiation segment held the largest market share, while the extracorporeal laser blood irradiation segment is anticipated to exhibit the highest CAGR of 7.8% during the forecast period.

By end user, the market is divided into hospitals, blood banks, diagnostic clinics, and research institutes. The hospitals segment accounted for the largest share in 2021, but the blood banks segment is projected to grow at the highest CAGR of 7.7% during the forecast period.

In terms of indications, the market is segmented into acute leukemia, solid tumors, pelvic tumors, lymphoma, and others. The acute leukemia segment held the largest market share in 2021, while the lymphoma segment is expected to register the highest CAGR of 8.8% in the coming years.

Data from reputable sources such as the World Health Organization (WHO), Globocan, World Bank, National Health Service (NHS), National Library of Medicine (NLM), and Eurostat were utilized in the preparation of this report on the blood irradiation market.